From Single Cytokines to Networks: A Systems Immunology View of Ulcerative Colitis
- 21 July 2026
- journal article
- review article
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 45 (10) , 475-479
Abstract
Ulcerative colitis (UC) is a chronic immune-mediated disorder of the gastrointestinal tract underpinned by dysregulated mucosal immune responses. Although biological therapies targeting individual cytokines have improved clinical outcomes, most patients fail to achieve durable remission, highlighting the limitations of single-target approaches. Emerging evidence suggests that cytokines function not in isolation but within highly interconnected signaling networks. Systems-level analyses using single-cell transcriptomics and network-based reconstruction reveal that UC phenotypes are characterized by specific rewiring of cytokine communication. Longitudinal multi-omics data, ex vivo perturbation models, and spatial transcriptomics offer opportunities to extend this framework by resolving the spatiotemporal dynamics of cytokine communication across disease states. Integration with systems genomics and microbial–metabolic networks could further refine patient-specific cytokine models. Together, this multi-layered framework supports a paradigm shift away from reductionist, single-cytokine approaches toward a dynamic, spatially organized, and genetically constrained systems immunology perspective of mucosal inflammation, informing novel precision medicine strategies.Keywords
This publication has 26 references indexed in Scilit:
- Integrating multi-omics to unravel host-microbiome interactions in inflammatory bowel diseaseCell Reports Medicine, 2024
- Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in GermanyInternational Journal of Colorectal Disease, 2023
- Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapyNature Communications, 2022
- A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitisNature Communications, 2022
- Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm StudyClinical Gastroenterology and Hepatology, 2021
- Breaking the therapeutic ceiling in drug development in ulcerative colitisThe Lancet Gastroenterology & Hepatology, 2021
- Ulcerative colitisNature Reviews Disease Primers, 2020
- Pathway paradigms revealed from the genetics of inflammatory bowel diseaseNature, 2020
- Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel diseaseNature Medicine, 2017
- Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel diseaseNature Genetics, 2017